Allogeneic hematopoietic cell transplantation for inborn metabolic diseases

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Clinical experience for more than two decades has shown that allogeneic HCT may benefit some but not all patients with inherited metabolic diseases. The HCT procedure is most effective in pre-symptomatic patients and those with indolent forms of storage diseases but is ineffective in those with overt neurological symptoms or aggressive neonatal or infantile forms. HCT alone does not correct skeletal dysplasia in MPSs and may not prevent development or progression of the peripheral neuropathy in sphingolipidoses and ALD. Decisions regarding HCT in patients with storage diseases should be made by investigators knowledgeable about these diseases, with judicious use of laboratory and clinical resources necessary to reach the best therapeutic decision for the individual patient.

Original languageEnglish (US)
JournalAnnals of Hematology
Volume81
Issue numberSUPPL. 2
StatePublished - 2002
Externally publishedYes

Fingerprint

Metabolic Diseases
Cell Transplantation
Sphingolipidoses
Peripheral Nervous System Diseases
Research Personnel
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Allogeneic hematopoietic cell transplantation for inborn metabolic diseases. / Yeager, Andrew M.

In: Annals of Hematology, Vol. 81, No. SUPPL. 2, 2002.

Research output: Contribution to journalArticle

@article{a89e3c79590e45e1b0bb4fecbd903505,
title = "Allogeneic hematopoietic cell transplantation for inborn metabolic diseases",
abstract = "Clinical experience for more than two decades has shown that allogeneic HCT may benefit some but not all patients with inherited metabolic diseases. The HCT procedure is most effective in pre-symptomatic patients and those with indolent forms of storage diseases but is ineffective in those with overt neurological symptoms or aggressive neonatal or infantile forms. HCT alone does not correct skeletal dysplasia in MPSs and may not prevent development or progression of the peripheral neuropathy in sphingolipidoses and ALD. Decisions regarding HCT in patients with storage diseases should be made by investigators knowledgeable about these diseases, with judicious use of laboratory and clinical resources necessary to reach the best therapeutic decision for the individual patient.",
author = "Yeager, {Andrew M}",
year = "2002",
language = "English (US)",
volume = "81",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation for inborn metabolic diseases

AU - Yeager, Andrew M

PY - 2002

Y1 - 2002

N2 - Clinical experience for more than two decades has shown that allogeneic HCT may benefit some but not all patients with inherited metabolic diseases. The HCT procedure is most effective in pre-symptomatic patients and those with indolent forms of storage diseases but is ineffective in those with overt neurological symptoms or aggressive neonatal or infantile forms. HCT alone does not correct skeletal dysplasia in MPSs and may not prevent development or progression of the peripheral neuropathy in sphingolipidoses and ALD. Decisions regarding HCT in patients with storage diseases should be made by investigators knowledgeable about these diseases, with judicious use of laboratory and clinical resources necessary to reach the best therapeutic decision for the individual patient.

AB - Clinical experience for more than two decades has shown that allogeneic HCT may benefit some but not all patients with inherited metabolic diseases. The HCT procedure is most effective in pre-symptomatic patients and those with indolent forms of storage diseases but is ineffective in those with overt neurological symptoms or aggressive neonatal or infantile forms. HCT alone does not correct skeletal dysplasia in MPSs and may not prevent development or progression of the peripheral neuropathy in sphingolipidoses and ALD. Decisions regarding HCT in patients with storage diseases should be made by investigators knowledgeable about these diseases, with judicious use of laboratory and clinical resources necessary to reach the best therapeutic decision for the individual patient.

UR - http://www.scopus.com/inward/record.url?scp=0036996004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036996004&partnerID=8YFLogxK

M3 - Article

C2 - 12611061

AN - SCOPUS:0036996004

VL - 81

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - SUPPL. 2

ER -